A long-term study of low-dose aerosolized terbutaline sulfate.
The purpose of this study was to evaluate the safety and efficacy of a new lowdose terbutaline sulfate aerosol (375 micrograms) over a six-week period. The question of drug tolerance was also evaluated. Twenty-four ambulant patients with chronic obstructive pulmonary disease with a component of reversible airway disease was evaluated. The patients were tested at two-week intervals during a six-week period. The patients abstained from all bronchodilatory medications for at least 10 hours prior to the time of evaluation. The evaluation consisted of baseline FEV1 and MMEFR determinations, ECG, CBC, urinalysis, and renal and liver function tests. After the terbutaline was administered, a rhythm strip and pulmonary function tests were repeated at 5, 15, 30, 60, 120, and 180 minutes. Throughout the six-week study there was a statistically significant increase in FEV1 and MMEFR, (P less than 0.001). No change was noted in the systolic blood pressures; however, heart rate and diastolic blood pressure decreased significantly. No drug tolerance, paradoxical bronchospasm, subjective side effects, no abnormal laboratory results were noted during the study period.
D000328:Adult; D000336:Aerosols; D000402:Airway Obstruction / Q000188:drug therapy* / Q000503:physiopathology; D001249:Asthma / Q000188:drug therapy; D001794:Blood Pressure; D005260:Female; D005541:Forced Expiratory Volume; D006339:Heart Rate; D006801:Humans; D008297:Male; D008450:Maximal Midexpiratory Flow Rate; D013726:Terbutaline / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000336:Aerosols; D013726:Terbutaline